感染：控制与治疗
Infection: Control and Treatment.
作者信息
Salina Elena G
机构信息
Bach Institute of Biochemistry Research Center of Biotechnology, Russian Academy of Sciences, 119071 Moscow, Russia.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
出版信息
Microorganisms. 2023 Apr 18;11(4):1057. doi: 10.3390/microorganisms11041057.
Abstract
Tuberculosis (TB) is the second leading infectious killer after COVID-19, causing 10 million new cases and claiming the lives of more than 1 [...].
摘要
结核病（TB）是仅次于新型冠状病毒肺炎的第二大致命传染性疾病，每年新增1000万病例，夺走超过1[……]人的生命。
相似文献
1
Infection: Control and Treatment.感染：控制与治疗
Microorganisms. 2023 Apr 18;11(4):1057. doi: 10.3390/microorganisms11041057.
3
Mycobacterium tuberculosis.结核分枝杆菌。
Trends Microbiol. 2018 Jun;26(6):555-556. doi: 10.1016/j.tim.2018.02.012. Epub 2018 Mar 23.
4
Tuberculosis and HIV - deadly co-infection.结核病与艾滋病病毒——致命的合并感染。
AIDSlink. 1996 Mar-Apr(38):1, 3.
5
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发：现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
6
[Recent progress in mycobacteriology].[分枝杆菌学的最新进展]
Kekkaku. 2007 Oct;82(10):783-99.
7
[Frontier of mycobacterium research--host vs. mycobacterium].[分枝杆菌研究前沿——宿主与分枝杆菌]
Kekkaku. 2005 Sep;80(9):613-29.
8
Tuberculosis Drug Discovery: Challenges and New Horizons.结核病药物发现：挑战与新视野。
J Med Chem. 2022 Jun 9;65(11):7489-7531. doi: 10.1021/acs.jmedchem.2c00227. Epub 2022 May 25.
9
Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.为结核病药物研发注入新动力：新型抗分枝杆菌靶点和药物。
Curr Opin Microbiol. 2018 Oct;45:39-46. doi: 10.1016/j.mib.2018.02.006. Epub 2018 Feb 23.
10
Selective delipidation of Mycobacterium bovis BCG enables direct pulmonary vaccination and enhances protection against Mycobacterium tuberculosis.分枝杆菌选择性去脂化使直接肺部接种成为可能，并增强了对结核分枝杆菌的保护作用。
Mucosal Immunol. 2019 May;12(3):805-815. doi: 10.1038/s41385-019-0148-2. Epub 2019 Feb 18.
引用本文的文献
1
Genomic decoding of drug-resistant tuberculosis transmission in Thailand over three decades.泰国三十多年来耐多药结核病传播的基因组解码
Sci Rep. 2025 Aug 13;15(1):29617. doi: 10.1038/s41598-025-15093-7.
本文引用的文献
1
MicroRNAs as Biomarkers of Active Pulmonary TB Course.微小RNA作为活动性肺结核病程的生物标志物
Microorganisms. 2023 Feb 28;11(3):626. doi: 10.3390/microorganisms11030626.
2
Epidemiology and Drug Resistance Patterns of in High-Burden Area in Western Siberia, Russia.俄罗斯西西伯利亚高负担地区的流行病学和耐药模式
Microorganisms. 2023 Feb 8;11(2):425. doi: 10.3390/microorganisms11020425.
3
Fighting Tuberculosis: In Search of a BCG Replacement.抗击结核病：寻找卡介苗的替代品
Microorganisms. 2022 Dec 23;11(1):51. doi: 10.3390/microorganisms11010051.
4
Dormancy: How to Fight a Hidden Danger.休眠：如何应对隐藏的危险。
Microorganisms. 2022 Nov 25;10(12):2334. doi: 10.3390/microorganisms10122334.
5
Genome-Wide Study of Drug Resistant and Its Intra-Host Evolution during Treatment.治疗期间耐药性及其宿主内进化的全基因组研究。
Microorganisms. 2022 Jul 17;10(7):1440. doi: 10.3390/microorganisms10071440.
6
Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors.作为分枝杆菌生长抑制剂的嘧啶核苷类似物。
Microorganisms. 2022 Jun 27;10(7):1299. doi: 10.3390/microorganisms10071299.
7
Immune evasion and provocation by Mycobacterium tuberculosis.结核分枝杆菌的免疫逃逸和免疫激发。
Nat Rev Microbiol. 2022 Dec;20(12):750-766. doi: 10.1038/s41579-022-00763-4. Epub 2022 Jul 25.
8
Biodiversity of in Bulgaria Related to Human Migrations or Ecological Adaptation.保加利亚与人类迁徙或生态适应相关的生物多样性。
Microorganisms. 2022 Jan 11;10(1):146. doi: 10.3390/microorganisms10010146.
9
Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs.克服结核病治疗中的原核生物/真核生物障碍：抗寄生虫药物重新利用和使用的前景。
Microorganisms. 2021 Nov 11;9(11):2335. doi: 10.3390/microorganisms9112335.
10
Small RNA MTS1338 Confers Pathogenic Properties to Non-Pathogenic .小RNA MTS1338赋予非致病性细菌致病特性。
Microorganisms. 2021 Feb 17;9(2):414. doi: 10.3390/microorganisms9020414.
Zotero 插件